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Evaluation of oxidant/antioxidant status and ECP levels in
asthma
Ömer EMECEN1, Berrin BERÇİK İNAL1, Füsun ERDENEN2, Murat USTA1, Hale ARAL1,
Güvenç GÜVENEN1

Aim: Inflammatory and immune cells, such as eosinophils, macrophages, and neutrophils, generate more reactive oxygen
species in patients with asthma than they do in healthy individuals, and oxygen radicals contribute to tissue injury in
asthma. We aimed to measure total oxidant status (TOS) and antioxidant status (TAS) in order to assess oxidative and
antioxidative capacity. Eosinophil cationic protein (ECP), total IgE, and eosinophils (%) were measured to evaluate the
level of inflammation.
Materials and methods: The study included 56 non-smoking asthma patients that were followed-up at the respiratory
disease and allergy outpatient clinics, where they received ongoing treatment for 5 months (May 2008-October 2008).
Patients with malignancy or chronic diseases, such as DM, chronic renal disease, and rheumatoid arthritis, were excluded.
The patients with asthma were divided into 2 subgroups according to the level of asthma control: controlled and partially
controlled.
Results: Despite the absence of statistically significant differences in TAS and TOS in the asthma and control groups (P
> 0.05), the levels of ECP, eosinophils, and total IgE were higher in the asthma patients (27.4-16 mg/dL, P = 0.008; 2.8%1.7%, P = 0.03; 59-19.3 IU/L, P < 0.001, respectively); there were no statistically significant differences between the
asthma subgroups.
Conclusion: Therapy administered to the asthmatic patients prevented generation of excess oxidants, although
eosinophilic inflammation persisted.
Key words: Asthma, oxidative stress, total oxidant status, total antioxidant status, eosinophil cationic protein

Astımda oksidan/antioksidan durumları ve ECP seviyelerinin değerlendirilmesi
Amaç: Eozinofiller, makrofajlar ve nötrofiller gibi inflamatuvar ve immün hücreler sağlıklı bireylerden daha fazla astımlı
hastalarda reaktif oksijen ürünleri meydana getirir; ve oksijen radikalleri astımdaki doku zedelenmesine katkıda
bulunurlar. Biz oksidatif ve antioksidatif kapasitenin değerlendirilmesi için total antioksidan (TAS) ve total oksidan
(TOS) seviyelerini astımlı hastalarda değerlendirmeyi amaçladık. ECP, total IgE ve (%) eozinofilleri gruplardaki
inflamasyonun seviyesini değerlendirmek için ölçüldü.
Yöntem ve gereç: Solunum hastalıkları ve Alerji kliniğinde takip edilen astımlı sigara içmeyen (n = 56), 5 aydır (Mayıs
2008-Ekim 2008) tedaviye devam eden hastalar çalışmaya dahil edildi. Biz malignensili hastaları veya diabetes mellitus,
kronik renal hastalık, romatoit artrit gibi kronik hastalıkları dışladık. Sonrasında, astımlı hastalar astım kontrol
seviyelerine göre kontrollü ve kısmi kontrollü olarak iki subgruba bölündü.
Bulgular: Astım ve kontrol gruplarında TAS ve TOS seviyeleri arasında farklılık istatistiksel olarak anlamlı olmamasına
rağmen (P > 0,05); ECP, eozinofil ve total IgE seviyeleri astım hastalarında daha yüksekti (27,4-16 mg/dL, P = 0,008; %
2,8-1,7, P = 0,03; 59-19,3 IU/L, P < 0,001, sırasıyla). Astımın subgrupları arasında farklılık gözlenmedi (P > 0,05).

Received: 03.06.2009 – Accepted: 20.05.2010
1
Department of Clinical Biochemistry, Ministry of Health İstanbul Education and Research Hospital, İstanbul - TURKEY
2
Department of Internal Medicine, İstanbul - TURKEY
Correspondence: Berrin BERÇİK İNAL, Department of Clinical Biochemistry, Ministry of Health İstanbul Education and Research Hospital, Central Clinical Chemistry
Laboratory-İstanbul - TURKEY
E-mail: berrin_inal@yahoo.com

889

Biomarkers of oxidative damage in asthma

Sonuç: Astımlı hastalarda tedavinin aşırı oksidan oluşumunu engellediği fakat eozinofilik inflamasyonunun sebat ettiği
sonucuna vardık.
Anahtar sözcükler: Astım, oksidatif stres, total oksidan status, total antioksidan status, eozinofil katyonik protein

Introduction
Bronchial asthma is a chronic inflammatory illness
that affects the airway due to the effects on various
cells, including mast cells, eosinophils, and T
lymphocytes, and other cellular components.
Eosinophils are the most important component of
inflammation in asthma. Eosinophil cationic protein
(ECP) is secreted by eosinophil granulocytes, has
cytotoxic effects on bronchial epithelium cells, and
causes lysis. ECP also complicates the pathogenesis of
asthma by causing histamine secretion by mast cells
and basophils. Eosinophils and the granule proteins
they produce, such as ECP, are important in
evaluating bronchial inflammation in asthma (1).
Free radicals are short-lived and independent
chemicals that have at least one unpaired electron in
their outer orbit. They form more stable structures by
reacting with other molecules (2). Free radicals may
be created via normal metabolic pathways or other
factors (3). Free radicals formed within an organism
are mostly derived from molecular oxygen. In certain
pathological conditions the quantity of free radicals
may increase due to the formation of a large number
of free oxygen radicals or inability of an organism’s
defense system to cope. These radicals interact with
various cellular components and macromolecules,
and cause metabolic, structural, and functional
damage that may lead to cell death. It is thought that
cell damage caused by free oxygen radicals contributes
to the pathogenesis of several chronic diseases,
including asthma.
Inflammatory and immune cells, including
macrophages, neutrophils, and eosinophils, produce
more reactive oxygen species in asthma patients than
in healthy individuals (3,4). Many characteristic traits of
asthma occur due to the production of hyper-reactive
oxygen species. Oxygen radicals are known to cause βreceptor dysfunction (3), bronchial smooth muscle
contraction (3), bronchial hypersensitivity (3,5,6),
increased mucin secretion (3,6), and a rise in vascular
permeability (3,6). Numerous studies suggest that in
890

asthma oxidative stress caused by overproduction of
various free radicals or by an insufficient antioxidant
defense system contributes to the tissue damage
induced by inflammatory cells (3-5,7-12).
In the present study patients being treated for
asthma were tested for total oxidant status (TOS) and
total antioxidant status (TAS) to determine their
oxidant-antioxidant state, and tested for ECP, as an
inflammation marker. The aim of this study was to
evaluate the levels of these parameters, and compare
them with those in healthy controls.
Materials and methods
Patient and control groups
The present study included study 56 patients (43
female, 13 male) diagnosed with asthma at the
İstanbul Education and Research Hospital Allergy
Clinic between May and October 2008, and 22 healthy
controls (15 female, 7 male). Asthma patients with
additional conditions related to oxidative stress, such
as cancer, eczema, and chronic illnesses (diabetes
mellitus, chronic kidney disease, etc.), or chronic
inflammation (rheumatoid arthritis, etc.) were
excluded from the study. Additionally, cigarette
smokers were excluded.
The level of control of asthma in the patient group
was evaluated based on the Global Strategy for Asthma
Management and Prevention (Global Initiative for
Asthma [GINA] 2007) (13). Based on the severity of
their condition, asthma patients consistently used low
to moderate doses of inhaled corticosteroids and
long-acting bronchodilators, or as needed, shortacting β2-agonists. The controls were not using any
drugs. Detailed anamneses, physical examinations,
and treatment plans for the asthma patients were
noted. Fasting blood samples were collected from the
patients and controls to measure TOS, TAS, ECP, and
total IgE, and to obtain hemograms. The patients and
controls underwent pulmonary function tests to
measure lung function.
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Collection and storage of samples
Serum samples were collected from the median
cubital vein into test tubes without anticoagulants
(Becton Dickinson Vacutainer® SST II Advance, BD
Diagnostics, Franklin Dakes, USA) for TOS, TAS,
ECP, and total IgE measurement. For TAS and TOS
measurement the blood samples were centrifuged at
1660 ×g, and sera were stored in portions at –80 °C in
Eppendorf tubes. The samples were brought back to
room temperature before being tested in an Abbott
Aeroset 2.0 analyzer (Abbott Laboratories, IL, USA).
For ECP and total IgE measurement the blood
samples were centrifuged at 1660 ×g for 10 min, and
immediately analyzed. To obtain hemograms blood
samples were collected from the median cubital vein
into EDTA tubes, and then immediately analyzed.
Evaluation of lung function
Lung function was measured using a Koko Legend
portable spirometer (Ferraris Respiratory Inc.,
Louisville, CO, USA).
Measurement of TAS
Measurement of TAS was performed using an
Aeroset 2.0 analyzer and a total antioxidant status kit
(Rel Assay Diagnostic, Turkey). With this kit the
reduced
ABTS
(2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonate)) molecule is oxidized to
ABTS•+, using hydrogen peroxide alone in an acidic
medium (acetate buffer 30 mmol/L; pH 3.6). In the
acetate buffer solution the concentrated (deep green)
ABTS•+ molecules remain more stable for a long time.
While it is diluted with a more concentrated acetate
buffer solution at high pH (acetate buffer 0.4 mol/L;
pH 5.8), the color is spontaneously and slowly
bleached. Antioxidants present in the sample
accelerate the bleaching rate to a degree proportional
to their concentrations. This reaction can be
monitored spectrophotometrically and the bleaching
rate is inversely related to the total antioxidant
capacity (TAC) of the sample. The reaction rate is
calibrated with Trolox, which is widely used as a
traditional standard for TAC measurement assays,
and the assay results are expressed as mmol Trolox
equivalent/L (14).
Measurement of TOS
Measurement of TOS was performed using an
Aeroset 2.0 analyzer and a TOS kit (Rel Assay

Diagnostic, Turkey). With this kit oxidants present in
the sample oxidize the ferrous ion–o-dianisidine
complex to ferric ions. The oxidation reaction is
enhanced by glycerol molecules, which are abundant
in the reaction medium. The ferric ions make a
colored complex with xylenol orange in an acidic
medium. The color intensity, which can be measured
spectrophotometrically, is related to the total quantity
of oxidant molecules in the sample. The assay is
calibrated with hydrogen peroxide and the results are
expressed as the micromolar hydrogen peroxide
equivalent per liter (μmol H2O2 Equiv./L) (15).
Measurement of ECP
ECP was measured in an Immulite 1000 analyzer
(Siemens Healthcare Diagnostics Inc., Deerfield, IL,
USA) using an Immulite 1000 ECP kit and the
chemiluminescent immunometric method.
Measurement of total IgE
Measurement of total IgE was performed in a
Beckman Coulter IMMAGE Immunochemistry
Systems analyzer (Beckman Coulter Inc., Fullerton,
CA, USA), using Beckman Coulter’s reagent and the
turbidimetric method.
Measurement of eosinophil (%)
Eosinophil (%) levels were measured using
hemogram tests, a Coulter GEN·S hematology
analyzer (Beckman Coulter Inc., Fullerton, CA, USA)
and a Coulter SCATTER PAK and LYSE S III Diff lytic
reactive kit.
Statistical analysis
Statistical analysis was conducted using SPSS for
Windows, v.11.5 (SPSS Inc., Chicago, IL, USA). The
Kolmogorov-Smirnov test was used to compare the
distribution of TAS, TOS, ECP, total IgE, and
eosinophil (%) in the patient and control groups. As
the group distribution of TOS, ECP, total IgE, and
eosinophil (%) values was skewed, the Mann-Whitney
U-test was used to compare the groups. Student’s ttest was used for statistical evaluation of TAS, which
was normally distributed.
Group distribution of the patients according to the
level of control of asthma (determined by GINA) was
evaluated using the Kolmogorov-Smirnov test. As the
group distribution of TOS, TAS, ECP, total IgE, and
eosinophil (%) values was skewed, the Mann-Whitney
891
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There was no statistically significant difference in
TAS, TOS, ECP, total IgE, or eosinophil (%) levels (P
> 0.05) between the controlled and partially
controlled patients (Table 3). Additionally, there was
a weak positive correlation (rs = 0.392, P < 0.001)
between ECP and total IgE levels, and a moderately
positive correlation (rs = 0.560, P < 0.001) between
ECP and eosinophil (%) levels (Table 4).

U-test was used for between-group evaluation of the
level of asthma control. Spearman’s rho was used for
correlation analyses in the asthmatic group. The level
of statistical significance was accepted as P ≤ 0.05.
Results
Mean age of the 56 patients was 36.2 ± 13.8 years,
versus 32.3 ± 8.54 for the 22 controls. As expected, the
predicted FEV1 was higher in the control group (106
± 14.3) than in the patient group (90.7 ± 19.07) (Table
1). There were no statistically significant differences in
gender, age, or serum TOS and TAS levels between
the patient and control groups (P > 0.05). A
statistically significant difference was observed in
serum ECP (P = 0.008), serum total IgE (P < 0.001),
and serum eosinophil (%) levels (P = 0.03) between
the patient and control groups (Table 2).

Discussion and conclusion
Bronchial asthma is an inflammatory disease
characterized by activation and accumulation of
inflammatory cells in the airway. This inflammation
causes tissue damage, resulting in the pathological
manifestations of the disease, including airflow
obstruction, airway hyperresponsiveness, and
permanent structural changes that include airway

Table 1. Demographic data-respiratory functions tests.
ASTHMA

HEALTHY CONTROL

56

22

36.2 ± 13.8

32.3 ± 8.54

43/13

15/7

90.7 ± 19.01

106 ± 14.3

N
a

Age (years)

Gender (female/male)
a
1

predicted FEV %
a

The data are expressed as mean values ± standard deviation.

Table 2. Study parameters based on asthma-healthy control group.

TOSa
(μmol H2O2 Equiv./L)

ASTHMA

HEALTHY CONTROL

P value

3.31 (1.45-15.67)

2.99 (2.14-11.1)

P > 0.05

1.34 ±0.13

1.32±0.20

P > 0.05

27.4 (6-200)

16 (5-83)

P = 0.008

2.8 (0-51)

1.7 (0-7)

P = 0.03

59 (5-805)

19.3 (5-111)

P < 0.001

b

TAS
(mmol Trolox Equiv./L)
a

ECP
mg/dL
a

Eosinophil (%)
eosinophil/leukocyte* 100
Total IgE
IU/L
a

a

The data are expressed as median values. Mann–Whitney U-test was used for statistical
analysis.
b
The data are expressed as mean value ± standard deviation. Student’s t-test was used for
statistical evaluation.
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Table 3. Study parameters based on asthma control levels.
CONTROL LEVEL
Controlled (n = 29)

Partly controlled (n = 22)

P value

TOS
(μmol H2O2 Equiv./L)

3.31 (1.45-15.6)

3.25 (1.63-6.57)

P > 0.05

TAS
(mmol Trolox Equiv./L)

1.33 (1.12-1.54)

1.32 (1.06-1.62)

P > 0.05

ECP
mg/dL

31 (6-200)

26 (6-94)

P > 0.05

Eosinophil (%)
eosinophil/leukocyte × 100

3.4 (0-50)

2.8 (0.8-11)

P > 0.05

58.5 (5-805)

77.5 (5-742)

P > 0.05

Total IgE
IU/L

The data are expressed as median values.

Table 4. Results of correspondence analysis based on Spearman’s rho in the asthma group.

ECP
TOS

TOS

TAS

Total IgE

Eosinophil (%)

0.118 - P > 0.05

0.048 - P > 0.05

0.392 - P < 0.001

0.560 - P < 0.001

-0.57 - P > 0.05

0.085 - P > 0.05

0.019 - P > 0.05

-0.25 - P > 0.05

0.264 - P < 0.05

TAS
Total IgE

0.465 - P < 0.001

The data are expressed as rs - statistical significance.

remodeling. Various bioactive mediators and
cytokines are involved in the pathogenesis of asthma.
Additionally, free oxygen radicals have negative effects
that result in the tissue damage associated with
asthma (7). It is well known that oxidative stress is an
important component in airway inflammation (16).
As in other inflammatory conditions, oxidative
burst in asthma is a non-specific event in which
numerous inflammatory processes are simultaneously
activated. Asthma mediators, such as lipid mediators,
chemokines, adhesion molecules, and eosinophil
granulocytes, are potential stimulators of oxidant
production (17) and increase reactive oxygen species
(ROS) production (9). In vitro exposure of structural
and inflammatory cells of the lungs to oxidants
stimulates the production of such proinflammatory
mediators as cytokines, chemokines and their

receptors, growth factors, arachidonic acid
metabolites, adhesion molecules, and ligands (3,9).
The lungs possess an advanced antioxidant system
that functions to protect them from exposure to
harmful oxidants (3,4,12); however, the oxidantantioxidant balance is disturbed in asthma (10,12). In
asthma free oxygen radicals are produced in excess
during oxidative stress, and cause cellular dysfunction
via lipid, protein, and DNA oxidation or nitration (35,10-12). Many characteristic traits of asthma appear
due to the overproduction of reactive oxygen species.
We used TOS to evaluate the oxidant state, and
TAS to evaluate the antioxidant state in patients with
mild asthma. Zeyrek et al. studied patients with mild
asthma and reported that the oxidant markers plasma
TOS and total peroxide, and the antioxidant marker
TAS were higher in the asthmatic group than in the
893
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healthy control group (18). In the present study we
did not observe a significant difference in the TOS
level, taken as an oxidant marker, between the mild
asthmatic patients and controls. Although we used the
same method, our results contradict those of Zeyrek
et al. (18).
The lack of a significant difference in TOS between
our asthmatic patients and controls might have been
due to the fact that the patients were stabilized with
inhaled steroids. Studies show that steroid treatment
slows oxidant production in asthma patients (9).
Hanazawa et al. reported that inhaled steroid
treatment impedes inflammation of the airway,
reduces oxidative load, and causes a decrease in the
nitric oxide and nitrotyrosine present in tidal breath
(19). Other studies reported that steroid treatment
decreases MDA, H2O2, and NO levels (20). Similarly,
inhaled glucocorticoids decrease the total nitrate and
nitrite levels in tidal breath and sputum (9).
The results of studies conducted on the
antioxidant state based on antioxidant markers vary.
For example, some studies reported elevated
erythrocyte and leukocyte superoxide dismutase
(SOD) levels, others reported decreased erythrocyte
SOD levels, and some reported that SOD levels in
erythrocytes (21), bronchoalveolar lavage (BAL) fluid,
and bronchial epithelium (22) do not change.
Likewise, there are studies that reported decreased
glutathione peroxidase (4,6,23) or vitamin C (4,23)
levels, no change in glutathione peroxidase or vitamin
C (21,24), and studies that report increased
extracellular glutathione peroxidase in the BAL fluid
(4).
The lack of a significant difference in the level of
the oxidant marker TOS between our patient and
control groups shows that our patients maintained an
oxidant-antioxidant balance and did not have high
oxidant load. This might be why we did not observe
activation of compensatory mechanisms during high

oxidant load, an increase in antioxidant levels, or a
decrease in antioxidant consumption due to oxidative
load.
We chose to classify our patients according to the
level of asthma control instead of the severity of
asthma, because we think that classification based on
severity at the time of presentation would have been
ineffective. Classification based on the severity of
asthma is useful for initial evaluation. However, the
parameters for determining severity during initial
evaluation, such as nighttime and daytime symptoms,
limitation of activity, and the number of attacks, can
improve with treatment and might not reflect a
patient’s current condition. Therefore, it is more
useful and valuable to evaluate the level of control of
asthma (13).
ECP and eosinophil levels were higher in the
patient group than in the control group, and there was
a positive correlation between ECP, and total IgE and
eosinophil (%) levels. These findings indicate that
inflammation due to eosinophil was present, but the
similarity in the TOS level between the groups
suggests that there was a lack of oxidative stress due to
overproduction of oxidants in the patient group.
Inflammation in asthma is a complex condition
that results from the interaction of numerous factors.
Inflammatory mechanisms, including overproduction
of oxidants, harm asthma patients and create the
observed symptoms; however, the present study’s
findings suggest that inflammation persisted, even in
the absence of oxidant overproduction. We did not
include newly diagnosed patients that had not
received treatment, which could be considered a
limitation of the present study. Another limitation is
the lack of evaluation of dietary intake of antioxidants.
We think that the evaluation of the oxidantantioxidant state and ECP levels in newly diagnosed
untreated asthma patients would provide data that
warrant additional research.
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